Linezolid is a synthetic antibiotic of oxazolidine class and active against most Gram-positive bacteria.
It acts a protein synthesis inhibitor stopping the growth of bacteria by disrupting their production of proteins (bacteriostatic action). The exact mechanism of action of linezolid appears to be unique in that it blocks the initiation of protein production, and not one of the later steps.
Packaging: KABIZOLID I.V. Injection Freeflex bag of 100 ml and 300 ml
| Dosage and Route of Administration | |||
| INDICATION | PEDIATRIC PATIENTS (BIRTH THROUGH 11 YEARS OF AGE) | ADULTS AND ADOLESCENTS (12 YEARS AND OLDER) | RECOMMENDED DURATION OF TREATMENT (CONSECUTIVE DAYS) |
| Nosocomial pneumonia | 10 mg/kg iv or oral every 8 hours | 600 mg iv or oral every 12 hours | 10 to 14 |
| Community-acquired pneumonia, including concurrent bacteremia |
10 mg/kg iv or oral every 8 hours |
600 mg iv or oral every 12 hours | 10 to 14 |
| Complicated skin and skin structure infections | 10 mg/kg iv or oral every 8 hours | 600 mg iv or oral every 12 hours | 10 to 14 |
| Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia | 10 mg/kg iv or oral every 8 hours | 600 mg iv or oral every 12 hours | 14 to 28 |
| Uncomplicated skin and skin structure infections | Less than 5 years: 10 mg/kg iv or oral every 8 hours, 5 - 11 years: 10 mg/kg iv or oral every 12 hours | Adults: 400 mg every 12 hours, Adolescents: 600 mg oral every 12 hours | 10 to 14 |
KABIZOLID l.V. lniection is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:
Linezolid solution for injection 2mg/ml
Each 100 ml contains
Linezolid IP 0.2 g
Dextrose (Anhydrous) IP 5.0 g
Water for Injections IP q.s.
